There are far more mechanisms to elucidate although, together with our in vitro data, FOXO1 might be the candidate to predict the chemotherapeutic response and it could be a molecular target for the treatment of drug-resistant ovarian cancers. This evidence concerns the gene FOXO1 and ovarian cancer.